Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

NCT03259425 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped DSMC Recommendation

Conditions

Melanoma

Interventions

DRUG: Nivolumab
DRUG: HF10

Sponsor

University of Utah

Collaborators

[object Object]
[object Object]